Multiple Sclerosis News and Research RSS Feed - Multiple Sclerosis News and Research

Multiple sclerosis (MS) is a severe autoimmune disease of the central nervous system that affects the brain and spinal cord, causing problems with muscle movement, balance and vision.

In MS, the protein coating called myelin, which protects nerves and helps electrical signals travel from the brain to the rest of the body, is damaged. The immune system, which usually fights infection, mistakes myelin for a foreign body and attacks it, stripping it from around the nerves. Exactly what causes this abnormal immune response is unclear, but research suggests a combination of both genetic and environmental factors.

The damaged myelin disrupts the transfer of nerve signals which may slow down, become distorted or stop altogether. This can cause severe symptoms ranging from vision loss through to muscle stiffness, loss of control over muscle movement, difficulties with balance and poor co-ordination.

Around 100,000 people in the UK have MS and it affects about three times as many women as men. The usual age at which diagnosis occurs is around 30, however, symptoms often first develop between the ages of 15 and 45.

Currently, there is no cure for MS but therapeutic approaches such as physiotherapy and steroid injections are used to manage the condition and ease symptoms.
Early exposure to marijuana can lead to immune-related diseases in adulthood

Early exposure to marijuana can lead to immune-related diseases in adulthood

When it comes to using marijuana, new research, involving mice and published in the October 2014 issue of the Journal of Leukocyte Biology, suggests that just because you can do it, doesn't mean that you should. That's because a team of Italian scientists have found that using marijuana in adolescence may do serious long-term damage to the immune system. [More]
AAN releases new position statement on opioids for chronic non-cancer pain

AAN releases new position statement on opioids for chronic non-cancer pain

According to a new position statement from the American Academy of Neurology, the risk of death, overdose, addiction or serious side effects with prescription opioids outweigh the benefits in chronic, non-cancer conditions such as headache, fibromyalgia and chronic low back pain. [More]
Diplomat's clinical technology manager honored as finalist in 2014 Next-Generation Pharmacist awards

Diplomat's clinical technology manager honored as finalist in 2014 Next-Generation Pharmacist awards

Diplomat, the nation's largest independent specialty pharmacy, is proud to announce that clinical technology manager Mike Crowe, PharmD, MBA, CSP, FMPA, was honored as a finalist in the 2014 Next-Generation Pharmacist awards. [More]
Dr. Nancy Chiaravalloti of Kessler Foundation receives Alumni Achievement in Science award

Dr. Nancy Chiaravalloti of Kessler Foundation receives Alumni Achievement in Science award

Nancy (Donofrio) Chiaravalloti, PhD, of Kessler Foundation received the Alumni Achievement in Science award from her alma mater, Muhlenberg College at the Alumni Association luncheon on September 13th. [More]
EMD Serono declares winners of first Grant for Oncology Innovation

EMD Serono declares winners of first Grant for Oncology Innovation

EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, today announced the winners of the first Grant for Oncology Innovation (GOI), who will receive grants totaling $1.3 million. [More]
People with memory loss more likely to develop dementia later, study finds

People with memory loss more likely to develop dementia later, study finds

New research suggests that people without dementia who begin reporting memory issues may be more likely to develop dementia later, even if they have no clinical signs of the disease. [More]
Pilot study shows benefits of psychoeducational wellness program in MS people

Pilot study shows benefits of psychoeducational wellness program in MS people

Kessler researchers have published a pilot study showing the benefits of a 10-week psychoeducational wellness program in people with multiple sclerosis (MS). Improvements were seen in mood, overall mental health, perceived stress, and pain. [More]
Phase IIa clinical trial data of ATL1102 in MS patients published in journal Neurology

Phase IIa clinical trial data of ATL1102 in MS patients published in journal Neurology

Antisense Therapeutics is pleased to report the publication of previously generated Phase IIa clinical trial data on ATL1102 in the medical journal Neurology. [More]
People who experience migraine in middle age may develop movement disorders later in life

People who experience migraine in middle age may develop movement disorders later in life

A new study suggests that people who experience migraine in middle age may be more likely to develop Parkinson's disease, or other movement disorders later in life. Those who have migraine with aura may be at double the risk of developing Parkinson's, according to the study published in the September 17, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Study links slowed processing speed with executive deficits in individuals with multiple sclerosis

Study links slowed processing speed with executive deficits in individuals with multiple sclerosis

Kessler Foundation researchers have published a study supporting the role of slowed processing speed in the executive deficits found in individuals with multiple sclerosis (MS). [More]

Johns Hopkins Multiple Sclerosis Center receives MS research grant from Progressive Alliance

The Johns Hopkins Multiple Sclerosis Center is the recipient of one of 22 research grants offered to investigators in nine countries by the International Progressive MS Alliance, a worldwide collaborative focused on finding solutions to progressive forms of multiple sclerosis (MS). [More]
UC Irvine study sheds light on cognitive losses

UC Irvine study sheds light on cognitive losses

Brain inflammation can rapidly disrupt our ability to retrieve complex memories of similar but distinct experiences, according to UC Irvine neuroscientists Jennifer Czerniawski and John Guzowski. [More]
Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that the U.S. Food and Drug Administration has granted Orphan Drug designation to the Company's proprietary SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis, more commonly known as whooping cough. [More]
Research gives scientists new insight into evolution of gibbon genome

Research gives scientists new insight into evolution of gibbon genome

A team led by an Oregon Health & Science University researcher has sequenced and annotated the genome of the only ape whose DNA had yet to be sequenced - the gibbon, an endangered small ape that inhabits the tropical forests of Southeast Asia. [More]
Study looks at blood type and risk of cognitive impairment

Study looks at blood type and risk of cognitive impairment

People with blood type AB may be more likely to develop memory loss in later years than people with other blood types, according to a study published in the September 10, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology. [More]
Pollution in many cities threatens brain development in children

Pollution in many cities threatens brain development in children

Pollution in many cities threatens the brain development in children. Findings by University of Montana Professor Dr. Lilian Calder-n-Garcidue-as, MA, MD, Ph.D., and her team of researchers reveal that children living in megacities are at increased risk for brain inflammation and neurodegenerative changes, including Alzheimer's or Parkinson's disease. [More]
Working memory may be underlying mechanism of cognitive reserve in MS

Working memory may be underlying mechanism of cognitive reserve in MS

Kessler Foundation scientists have shown that working memory may be an underlying mechanism of cognitive reserve in multiple sclerosis (MS). [More]
People with multiple sclerosis lose myelin in gray matter

People with multiple sclerosis lose myelin in gray matter

People with multiple sclerosis (MS) lose myelin in the gray matter of their brains and the loss is closely correlated with the severity of the disease, according to a new magnetic resonance imaging (MRI) study. [More]
Transparency Life receives SBIR program grant to fund Phase 2a proof-of-concept study for MS

Transparency Life receives SBIR program grant to fund Phase 2a proof-of-concept study for MS

Transparency Life Sciences, LLC (TLS), the world's first clinical-stage drug development company based on open innovation, today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive therapy for multiple sclerosis (MS). [More]
Findings may help develop biomarkers to identify HIV patients at risk of dementia

Findings may help develop biomarkers to identify HIV patients at risk of dementia

Since the introduction of the combination anti-retroviral therapy (cART) in the mid-90s, the life expectancy of HIV patients has significantly improved. As a result, long-term complications are becoming more relevant: almost every second HIV patient is affected by neurocognitive disorders, which can lead to dementia. [More]